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ABSTRACT 
The aim of this study was to develop and characterise an intranasal delivery system for amantadine (AMT).  
Optimal formulations (F) consisted of a thermosensitive polymer Pluronic® 127 (P127) and either carboxy methyl 
cellulose (CMC) or chitosan (CS) which demonstrated gel-transition at nasal cavity temperatures (34 °C ± 1 °C). 
Rheologically, the loss tangent (Tan δ) confirmed a three-stage gelation phenomena at 34 °C ± 1 °C and non-
Newtonian behaviour.  Storage of FCMC and FCS at 4 °C for 8 weeks resulted in repeatable release profiles at 34 
°C when sampled, with a Fickian mechanism earlier on but moving towards anomalous transport by week 8.  
Polymers (P127, CMC and CS) demonstrated no significant cellular toxicity to human nasal epithelial cells up to 4 
mg/mL and up to 1 mM for AMT (IC50: 4.5 mM ± 0.05 mM). FCMC and FCS demonstrated slower release across 
an in-vitro human nasal airway model (43-44 % vs 79 % ± 4.58 % for AMT).  Using a human nasal cast model, 
deposition into the olfactory regions (potential nose-to-brain) was demonstrated upon nozzle insertion (5 mm) 
whereas tilting of the head forward (15°) resulted in greater deposition in the bulk of the nasal cavity.  
 
 
KEYWORDS 
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INTRODUCTION 
Parkinson’s disease (PD) is an ageing associated progressive neurological disorder and affects 1.5 % of the 
population over 65-years of age 1, with age-adjusted prevalence rates thought to be around 150 per 100,000 with 
a suggested mean onset in the 70’s 1. Ageing is the largest single risk factor for the development of PD and the 
pathogenesis of PD is composed of a range of events leading towards neuronal apoptosis, primarily of 
degradation of dopamine neurones in the sustantia nigra. The mainstay of clinical drug therapy focuses on 
increases the levels of dopamine (DA) in the brain, with oral dosing of levodopa being the most commonly used 
to pharmacological intervention treatment to reverse the symptoms of PD.  It is also common to use adjunct 
therapies in conjunction with levodopa, such as the weak NMDA-type receptor antagonist amantadine, which 
can aid in blocking dopamine reuptake. 
 
One of the major complications of PD is the emergence of dysphagia affecting the ability to ingest/swallow and is 
a thought to affect between 45-95 % of PD patients 1,2 and has significant implications for orally dosed 
therapeutics such as amantadine and other anti-Parkinsonian therapeutics agents.  Furthermore the occurrence 
of bradykinesia and morning akinesia is often associated with delayed gastric emptying following the oral 
administration of anti-Parkinsonian therapeutics.  This is again confounded by the use of dopaminergic and other 
concomitant meditation interventions.  At least 24% of PD patients are thought to suffer from gastroparesis, the 
delay in empting of the stomach, which will inevitably impact upon clinical outcome of any orally administered 
medication. A more recent approach for therapeutic delivery is through the intranasal route to obtain systemic 
deposition as a practical alternative to oral and parenteral routes 3,4.   
 
The primary function of the nasal cavity is respiration and olfaction. The nasal cavity (in humans) is divided in to 
two symmetrical halves by a septum with each cavity sub-dived into four areas namely vestibules, atrium, 
respiratory region and olfactory regions.  With a surface area of 150 cm2, total volume of 15-20 mL the nasal 
cavity provides an optimal absorption area for drugs into the systemic circulations which would inevitably 
enhance the bioavailability of the therapeutic agent, particularly those which demonstrate poor oral absorption 
(intestinal permeation) or significant first-pass metabolism (extra-hepatic and hepatic) 5,6.  Although originally 
exploited for the delivery of locally acting agents (allergic of infections rhinitis, nasal pluposos and sinusitis) the 
highly vascularised nature of the nasal cavity has provided a portal for systemic delivery of small molecules and 
biomolecules 7. The nasal cavity can provide larger surface area for rapid systemic absorption due to its highly 
vascularised surface 8. This non-invasive route not only provides rapid onset of action, but often increased 
bioavailability in low doses as it bypasses the first pass metabolism 9.  
 
Although intranasal drug delivery offers many advantages, one of the main limitations is the short residence time 
of the formulation in the nasal cavity, as a result of mucociliary clearance (MCC) 10.  This movement involves the 
beating of mucocilia at a frequency of 1,000 strokes per minute and hence movement of mucus of 5 mm/minute 
11.  Thus the clearance of any nasally administered formulation further back towards to the nasopharynx is often 
a limiting factor in clinical administration and results in a short nasal residency half-life of 15-20 minutes 12. 
 
An ideal formulation would be one that was capable of prolonging residence time within the nasal cavity and 
therefore enhance the bioavailability of the drug.  To achieve this goal, the use of intelligent polymer based 
systems have now become more commonplace in this field and particularly the use of responsive systems which 
may respond to the nasal cavity temperature 13-22 or pH 23-27 have increased amongst researchers.  Furthermore, 
the use of mucoadhesive polymers 4,27-33 to enhance the adhesion of the formulations onto the nasal mucosa has 
further demonstrated the ability to prolong contact time with the mucosa and hence increase bioavailability 
10,15,18,23,34-36. 
 
The primary aim of this study was to develop an intranasal thermoresponsive hydrogel based delivery system for 
the delivery of anti-Parkinson’s drugs, using amantadine as a model candidate drug.  The study objectives were to 
utilise thermoresponsive polymers, for example Pluronic F127 (P127) 13, mucoadhesive polymers (carboxymethyl 
cellulose and chitosan) and surfactant (PEG4000 and PEG 12000) to aid and enhance formulation delivery and 
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retention within the nasal cavity using a multi-dose nasal spray and human nasal cast.  In order to develop and 
assess the formulations a range of studies were conducted and included rheological, stability, biological 
compatibility and nasal targeting of the formulations. 
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METHODS 
 
Materials 
Eagle’s Minimum Essential Medium (MEM), Dulbecco’s phosphate buffered saline (PBS), L-glutamine 200 mM, 
non-essential amino acids (NEAA), penicillin/streptomycin and trypsin-EDTA solution were obtained from PAA 
Laboratories (Austria); fetal bovine serum (FBS) (Labtech Intl Ltd. East Essex, UK); polyethylene glycol 4000 
(PEG4000), polyethylene glycol 12000 (PEG12000),  chitosan-medium molecular weight (CS), sodium chloride, 
potassium chloride, magnesium sulphate, calcium chloride, acetonitrile, orthophosphoric acid, acetic acid, 
ethanol, sodium hydroxide, potassium chloride and sodium chloride were obtained from Fisher Scientific 
(Loughborough, UK); gentamycin, (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) MTT, Trypan 
blue dye, Pluronic® F127 (P127), sodium carboxymethyl cellulose (CMC), amantadine hydrochloride (AMT), 
sodium metabisulphate, mucin from porcine stomach, boric acid, dimethyl sulfoxide (DMSO) and benzalkonium 
chloride were obtained from Sigma-Aldrich (St. Louis, MO, USA).  
 
Formulation development 
Formulations were initially prepared by a modified ‘Cold method’ approach as originally described by Schmolka 
(1973) 13. Briefly fixed quantities of excipients were utilised in all formulations and consisted of d-sorbitol 
(humectant) (0.5 % w/v), sodium metabisulphate (antioxidant) (0.1 % w/v) and benzalkonium chloride 
(surfactant) (0.1 % w/v). Additional polymers were incorporated and included mucoadhesives (CMC and CS) and 
permeation enhancers37/modulators of gelation temperature14,38 (PEG4000 and PEG 12000) at concentrations 
between 0.5-1.5 % w/v.  These components were combined with ultrapure water under constant stirring.  This 
was followed by AMT (0.5-1.5 % w/v) and the resulting solution was kept in an ice bath for 2 hours prior to the 
dropwise of P127 (15-20 %) and storage at 4 °C for 12 hours.  Prior to use, the pH of all formulations were 
adjusted to 5.516,39. Formulations were developed according to variation in the concentration of P127, 
mucoadhesive polymer, and drug content. 
 
Sol-gel transition (Tsol-gel)  
A modified method described by Zaki et al. 8 was used to determine the sol-gel transition temperature (Tsol-gel). A 
sample of each formulation (1 g) was transferred to a glass vial and heated in a dry block (Techne Dri-Block ® DB-
2D), initiated at 20 °C and increased by 1 °C after every 5 minutes of equilibration time. The Tsol-gel point was 
defined as the temperature whereby the upper meniscus of the gel did not move upon tilting the vial by 90 ° and 
this was used to demark optimal formulations. The optimal subset of formulations were then further 
characterised. 
 
Rheological characterisation 
To assess the rheological properties of the formulations, rheological measurements were carried out on AR-G2 
Rheometer (TA Instruments, USA), using parallel plate geometry with 40 mm steel plates having a gap 1.0 mm. 
The approximate sample volume used was 1.26 mL and the instrument was used in the oscillatory mode in the 
linear viscoelastic range of the sample. Steady state behavior was assessed at ambient (18 °C) and nasal (34 °C) 
temperatures over a shear rate range from 0.1 to 100 s-1.  
 
To quantify the rheological properties, the Ostwald-de Waele relationship (often called the power law) was 
applied to relate the shear stress (σ) is related to a consistency coefficient (k), the shear rate (?̇?) and an index 
value (n):   
𝝈 = 𝒌?̇?𝒏 
which is applicable to the formulations in light of the constant shear viscosity curves. In the context of rheology, 
the index value can be used to determine the type behavioural flow, with Newtonian behaviour when n = 1. 
When the magnitude of n is < 1, the underlying rheological process is shear-thinning (pseudoplastic flow) and 
then when n > 1 the fluid is shear-thickening.  
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In-vitro mucoadhesion   
The method of Nakamura et al. (1996) 24 was adapted to measure the mucoadhesion of the formulation systems.  
Briefly, 100 g of a hot 1 % agar and 2 % mucin mixture in PBS (pH 6.0) was cast onto a glass plate and left to gel at 
4 °C for 12 hours. The gel plate was then equilibrated at 34 °C for 1 hour followed by the application of a 250 µL 
sample of each formulation when the plate was kept at a 45° angle at 34 °C. This process was repeated using a 1 
% agar mixture (without mucin) and the mucoadhesion of the formulations were calculated by a ‘displacement’ 
value (measured in cm) reflecting the difference in gel movement in the presence and absence of 2 % mucin. 
 
AMT derivatisation and HPLC detection  
To quantify the release of AMT from the formulations, a pre-column derivatisation method for memantine was 
modified in order to enable detection of AMT 40. Briefly, to 50 µL of sample or standard solution of AMT, 40 µL of 
0.015 M FMOC and 50 µL of 0.5 M borate buffer were added and kept at room temperature for 20 minutes prior 
to the addition of 360 µL of a 0.05M borate buffer:acetonitrile (50:50 v/v) diluent. A Shimadzu HPLC system was 
used with a Phenomenex Luna C18 (150 × 4.6 mm) 5 µm column. The mobile phase consisted of phosphate 
buffer:acetonitrile (20:80 v/v).  The column was maintained at 30 °C and 10 µL injected.  The flow rate was 
maintained at 2 mL/minute with run time of 7 minutes. The UV detection of derivatised AMT was measured at 
265 nm. The intra/inter-day precision was determined and the limit of detection (LOD) and limit of quantitation 
(LOQ) were calibrated according to ICH (QR (R1)) recommendations 41. 
 
Stability assessment 
Optimised formulations were stored in stability cabinets maintained at 4 ± 1 °C (Sanyo Medicool, UK) and 25 ± 2 
°C (Firlabo, France) at a humidity of 60 % ± 5 %. The stability of the formulation was assessed based on the 
gelation of a sample of the formulation at 34 °C within 5 minutes, followed by assessment of the extent of drug 
release. 
 
The release of AMT from the formulations were assessed by a ‘membrane-less’ diffusion system 20,42,43.  A mass of 
formulation (0.25 g) appropriate for the nasal cavity volume was transferred to a glass vial and allowed to 
equilibrate in a dry block at 34 °C. Artificial nasal electrolyte (ANE) (0.8 g/L NaCl, 3 g/L KCl, and 0.45 g/L CaCl2, pH 
6.8) 44 was used as release media and 100 µL transferred onto the gelled formulation. This volume was 
completely withdraw and replaced with fresh ANE at each time point. Samples were analysed by a pre-column 
derivatisation method followed by HPLC analysis. 
 
In-vitro drug release kinetics 
Several kinetic drug release mathematical models were used to assess drug release from the formulations. The 
best-fit to the mathematical models described below confirmed the appropriate release kinetics: 
Higuchi model: 
𝑀𝑡
𝑀∞
= 𝑘𝐻 ∙ 𝑡
1
2 
where Mt/M∞ is the drug fraction released at time t and kH is the Higuchi constant. 
Zero order model: 
𝑀𝑡
𝑀∞
= 𝑘0 ∙ t 
where Mt/M∞ is the drug fraction released at time t and k0 is the zero-order release constant. 
First order model: 
𝑀𝑡
𝑀∞
= 1 − 𝑒−𝑘1𝑡 
where Mt/M∞ is the drug fraction released at time t and k1 is the first-order release constant. 
Power law: 
𝑀𝑡
𝑀∞
= 𝑘𝐾𝑃 ∙ 𝑡𝑛 
where Mt/M∞ is the drug fraction released at time t, kKP is a kinetic constant which describes the structural and 
geometrical elements of the formulations and n is the release exponents which is used to indicate the 
mechanism of drug release. The power law, otherwise known as the Korsmeyer-Peppas power law 45, has been 
used in many pharmaceutical formulations 46-49. The value of n is important in understanding the mechanism of 
release when it is unknown and often polymeric formulations can be categorised accordingly to this scale. When 
n ≤ 0.45 drug release is diffusion controlled and sometimes referred to as Fickian diffusion and when n > 0.89 the 
diffusion is indicative of erosion controlled drug release or class-II kinetics. For situations where 0.45 < n ≤ 0.89 
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the diffusion is a complex mixture of both processes and often termed anomalous transport. In all cases this is 
based on the assumption of release from a cylinder and applied to cumulative release rates < 60 % 45. 
 
Human nasal epithelial cell culture model  
The immortalised human nasal epithelial cell line RPMI 2650, was used to assess the compatibility of the 
formulations with human nasal epithelia and to develop an in-vitro nasal epithelial cell culture model 50 to assess 
drug release/transport.  Cells were grown in MEM supplemented with 10 % FBS, 1 % L-glutamine, 1 % NEAA, 1% 
penicillin-G/streptomycin in a humidified 37 °C incubator with 5 % (v/v) CO2 51. The media was changed every 2 
days.  
 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) (MTT) assay 
To assess cellular toxicity, RPMI 2650 cells were seeded at a density of 4x104 cells per well of a 96-well plate and 
allowed to attach for 24 hours. The media was removed and replaced with 200 µL of media containing either 
AMT (0.01-50,000 µM), mucoadhesive polymers or P127 (10-4000 µg/mL) and incubated for 24 hours at 37 °C in 
a 5 % (v/v) CO2 humidified air environment. Subsequently 20 µL of 5 mg/mL MTT dissolved in PBS was added to 
each well and incubated at 37 °C in a humidified air environment for 4 hours. After incubation the medium was 
removed and 100 µL of DMSO was added and the plates left to incubate for 15 minutes in the dark.  The UV-
absorbance of the formazan product was determined at 595 nm. Each concentration was assayed in eight wells 
and run in three independent experiments and results expressed as percentage cytotoxicity relative to a control 
(0.5% DMSO).   
 
Human nasal epitheial airway cell culture model: AMT transport 
To assess the release and transport of AMT from formulations, an in-vitro nasal epithelial airway cell culture 
model was developed with RPMI 2650 cells seeded onto collagen-coated 6-well permeable inserts (ThinCertsTM) 
at a seeding density of 4x105 cells/cm2 52 50 and grown for 14 days.  On days 10-14 an air-liquid interface (ALI) was 
initiated with the removal of apical media.  The integrity of the monolayer was determined by measuring the 
trans-epithelial electrical resistance (TEER) using an EVOM epithelial voltohmmeter (World Precision Instruments 
Inc.). Inserts were deemed acceptable where the TEER value was above 180 Ω.cm2 52 50. 
 
Immediately prior to the start of the transport study, maintenance media was replaced with transport media 
(HBSS with 25 mM HEPES) and the cells left to acclimatise for 30 minutes in a humidified 37 °C incubator with 5% 
(v/v) CO2.  A 1 mL sample of formulation was placed into the apical chamber, after removal of transport media 
from apical and basolateral compartment, and returned to the incubator for 5 minutes.  Once gelled, fresh 
transport media was placed into the basolateral chamber and 250 µL samples withdrawn at 5, 15, 30, 60, 120, 
150 and 180 minutes and replaced with fresh pre-warmed media.  Withdrawn samples were derivatised and AMT 
release quantified by HPLC analysis. 
 
Nasal spray systems: droplet size distribution 
To assess the potential in-vivo deposition characteristics of the proposed nasal formulation, a multi-dose pump 
spray delivery system was employed to characterise the formulation droplet size distribution using a laser 
diffraction technique.  The HELOS (Sympatec, UK) system was used with an R3 lens (measuring range 0.5-175 
µm).  The nasal pump was vertically mounted 3 cm away from the laser path and a vacuum source was mounted 
anterior to the pump system.  The pump systems were pre-actuated prior to mounting, and actuated three times 
to detect the particle size distribution.   Data was reported as volume diameters at 10 %, 50 % and 90 % of the 
cumulative undersized volumes. Span was calculated as: [(Dv90-Dv10)/Dv50]. 
 
Nasal spray system: human nasal cast deposition  
To assess the potential in-vivo deposition characteristics of the proposed nasal formulation, a multi-dose pump 
spray delivery system was employed to assess the deposition of formulations into an anatomically correct human 
nasal cast model (Koken Ltd, Japan).  The inner surface of each nostril was evenly coated in a water-indicated dye 
(Kolor Kut, USA).  Formulations were loaded into the spray pump, pre-actuated, before one actuation was 
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delivered into the nasal cast where the cast was fixed in an upright head position.  The impact of spray angle and 
nostril insertion depth on nasal deposition was analysed through photographing colour changes.  The captured 
images were subsequently processed through pixel quantification software to quantify the deposition patterns 
and calculate the deposition surface area 53.  The depositions of within the nasal cast was classified according to 
the predominate regions of deposition within the cast, i.e. lower nasal regions (nasal vestibule), the 
middle/upper nasal regions (turbinates) and the olfactory regions were assessed. 
 
Statistical analysis 
Unless otherwise stated, three independent experiments were carried out for each study. Statistical significance 
was evaluated by one-way ANOVA or paired two-tail Students t-test using GraphPad Prism version 6.00 for 
Windows (GraphPad Software, La Jolla California USA, www.graphpad.com). Calculations of IC50 were 
determined using a four-parameter logistic sigmoidal fitting function within GraphPad Prism.  Unless otherwise 
states, data is reported as mean ± standard deviation (SD). A significance level (p-value) of < 0.05 was considered 
as statistically significant. 
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RESULTS AND DISCUSSION 
The treatment of age-associated degenerative CNS disorders such as Parkinson’s diseases, poses particular 
difficulties in the design of appropriate drug delivery systems capable of overcoming the hindrances associated 
with dyskinesia and dystonia that are inherent in current pharmacological interventions for PD.  Although 
reformulation of existing orally dosed formulations may provide some benefit there is an inherent need to 
provide an alternative delivery routes of a range of CNS disorders which can both provide ease of clinical use but 
also improve the bioavailability of the therapeutic. 
 
The nasal mucosa fulfils this purpose in light of the large and vascularised route of access for drugs to the 
systemic circulation and can provide a relatively non-invasive approach to delivery drugs. 
 
A key concern of any nasal administered formulation is the residency of the formulation within the nasal cavity. 
Existing formulations are often associated with a nasal drip or ‘run-off’ effect which potentially diminish the 
bioavailability of nasal formation.  A novel development in this area has been the formulation of intelligent 
response based hydrogel nasal formulations which act to enhance residency within the nasal cavity 13-27. 
 
Sol-gel transition (Tsol-gel)  
The initial screening and optimisation resulting in 32 formulations, of which 3 demonstrated optimal gelation at 
the nasal cavity temperature of 34 °C ± 1°C 54.  These formulations were identified as FCMC (1 % w/v CMC), FPEG 
(1 % w/v PEG4000) and FCS (0.1 % w/v chitosan) and which all contained 17 % w/v P172 and 1% w/v amantadine 
(in addition to excipients). 
 
Rheological behaviour 
When assessing the properties of thermoresponsive gel-like systems, the storage/elasticity modulus (G′) and the 
loss modulus (G′′) are key metrics to describing the rheology of the formulation.  The elasticity modulus is an 
important metric in this regard and measures the energy stored and which is subsequently recovered for each 
cycle of deformation 55. It presents with lower values with reduced temperatures but significantly increases with 
an increase in temperature, and the point at which G′ overtakes G′′ indicates the initiation of the gelation 
phenomena. To assess this phase transition the ratio of G′′ and G′ (the loss tangent, Tan δ) was used, and where a 
phase-transition occurs an abrupt change in Tan δ is observed with values of < 1 indicating a greater G′ compared 
to G′′, indicative of gel formation.  This phase transition is often associated with three distinct phases: (i) an initial 
stable liquid phase plateau at low temperatures; (ii) an abrupt transition phase during the gelation process; (iii) a 
late stage stable gel plateau. 
 
All formulation demonstrated a gelation phenomenon, which initiated at approximately 26-28 °C, and was 
preceded by the stable plateau region (Figure 1). FCS and FCMC (Figure 1A) demonstrated a complete profile 
with three distinct phases culminating in a stable gel formulation, whereas FPEG (Figure 1A) only demonstrated 
two phases, plateau followed by a partial gelation phase, but did not form a stable a gel at the termination of the 
study (34 °C).  
 
The rate of gelation is also a key determinant of residency within the nasal cavity and this was assessed through a 
time-sweep analysis at a fixed temperature (34 °C).  FCMC demonstrated the quickest gelation of 28 ± 2 seconds 
which was followed by FCS (37 ± 3 seconds) and FPEG (68.5 seconds) (Figure 1B). 
 
At nasal cavity temperatures, a significant shear thinning behaviour was observed in all formulations, indicative 
of temperature-induced gel formation when compared to ambient temperatures (Figure 2), with viscosities for 
34 °C being statistically significantly different to those at 18 °C (P < 0.0001).  Furthermore, at 34 °C no significant 
difference in viscosity was reported over the shear rate studied (p = 0.227), however FPEG demonstrated a 
statistically significant lower viscosity compared to FCS and FCMC (P < 0.01). 
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As the shear rate increased from 0.091 to 100 s-1, the viscosity of the formulations dropped by 990-fold (FCMC), 
409-fold (FCS) and 207-fold (FPEG) (Figure 2).  However, all formulations exhibited non-Newtonian behaviour at 
nasal temperatures compared to Newtonian behaviour at ambient temperatures (Table 1). 
 
From an interpretation of the Ostwald model, the gel structure can be changed as a result of any deformation 
induced changes in the gel particles, through changes in the alignment of the polymer chains and also any 
changes in the interactions between polymer chain segments and any side chains. Therefore, upon heating the 
values of n will be lower in for stronger gels due to an increase in the noncovalent forces of between 
neighbouring particles 56.  
 
It was also apparent that the presence of different mucoadhesives can significantly alter the behaviour of the 
formulations.  For examples, the viscosity of FCMC was always higher than all other formulations, and particularly 
at 34 °C where there is an approximate 8-fold difference between FCMC and FPEG. Furthermore, the FCMC 
demonstrated a much lower n-value compared to FCS and FPEG (Table 1), suggesting a stronger gel formation at 
34 °C.  This phase represents the gradual conversion into a highly viscous/solid state.  During this phase the 
intricate hydrogen-binding network between the unimers of F127 and water molecules are disrupted and drives 
the formation of micelles, which further aggregate to form the physical gel-like structure. 57. On the basis of 13C 
NMR studies Pisal 58 suggested that at high temperature, conformational changes in the methyl group of the 
polyoxypropylene within the hydrophilic micellar region and in the motion of the hydrophilic end chains takes 
place. This results in dehydration and end chain friction, which causes the gelation.  
 
In-vitro mucoadhesion 
Mucoadhesion is defined as a state where at least one biological material is held with another material for a 
prolonged period of time 59.  In the context of drug delivery, this can be defined as the adhesion of an artificial 
material (such as a polymer system) to a biological substrate material 60.  We assessed the mucoadhesion of 
optimized formulations using an inclined-plate method in the presence and absence of mucin 24, with 
mucoadhesion assumed to have occurred if the displacement of the formulation in the absence of mucin is 
greater than in the presence of mucin. 
 
The displacement transfer test demonstrated that all formulations showed a statistically significant (P ≤ 0.001) 
displacement in the absence of mucin (Figure 3).  The difference between the absence and presence of mucin is 
indicative of the displacement effect and FCMC demonstrated the least extent of displacement (2.26 cm) with 
FPEG demonstrating the greatest extent of displacement (3.8 cm). 
 
The superiority of FCMC and FCS, compared to FPEG, is presumed to be a function of the enhanced rheological 
properties FCMC and FCS possess (Figure 1 and 2).  The fact that displacement is observed in the absence of 
mucin would indicated that the use of is able to recover some of the mucoadhesive properties of the 
mucoadhesive polymers included within the formations, and although known to show less biophysical properties 
as compared to native mucin, this purified mucin has less batch-to-batch variation and hence provides better 
reproducibility in measuring mucoadhesive force 61. 
 
AMT derivatisation and HPLC detection  
The HPLC was successfully able to detect the derivatisation of AMT with a retention time of 4.4 minutes.  
Percentage RSD for system precision (0.120 %) and method precision (0.121 %) were within the acceptable limits 
of 1 % and 2 % respectively.  
 
The linearity response of amantadine was determined using concentrations ranging from 0.0078 to 1.0 mg/mL 
and the response was linear over the specified range with a correlation coefficient of  0.9998, a slope of 1385904 
± 33080 and an intercept of -13515 ± 1045.  The validity was verified by ANOVA with no deviation from linearity. 
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Stability assessment 
To assess the stability of the optimised formulations, batches were prepared and stored in stability cabinets at 25 
°C/60 % RH and 4 °C for 8 weeks, with sampling at weekly intervals followed by assessment of AMT release 
conducted at nasal temperatures (34 °C).  A prerequisite for conducting release studies was the successful 
gelation of the stability samples prior to initiation of release studies. 
 
All formulations stored at 4 °C demonstrated successful sol-gel transition prior to the initiation of the release 
studies, confirming the thermoresponsive nature of the gel systems was maintained during the stability study 
duration.  However only FCS demonstrated successful sol-gel transition when stored at 25 °C/60 % RH for 2 
weeks, confirming that storage of formulations would be more appropriate at ‘refrigerated’ conditions to ensure 
stability of the products. 
 
The cumulative percentage release at preparation and after 1 week storage at 4 °C were not significantly 
different for all formulations, reaching 15-17 % release (Figure 4A).  Following 8 weeks storage at 4 °C, the 
quantity of AMT released from FCMS (16.15 % ± 0.82 %) was not significantly different to that at week 0 (16.86 % 
± 1.13 %) (Figure 4B), however at earlier time-points during the release study (30-120 minutes) significant 
differences (p < 0.05) in the AMT quantity released were apparent (Figure 4B).  For FCS, the amount of AMT 
released following 8 weeks storage at 4 °C (18 % ± 0.99 %) was significantly (p < 0.05) greater than that at week 0 
(15.32 % ± 0.30 %) (Figure 4B).  Significant differences in the release profile were also apparent during the initial 
phases of the release study (30-60 minutes) (Figure 4B). 
 
As the formulations presented are inherently based on ‘swellable’ type polymer systems, the diffusion was also 
modelled by the Korsmeyer-Peppas power law and generally demonstrated Fickian-type diffusion early on 
(except for FCS).  By week 8 this had moved towards anomalous transport (Table 2), whereby drug diffusion and 
the polymer relaxation were contributing to the overall release kinetics. 
 
The movement towards anomalous transport can be explained by considering the relationships between the two 
driving forces influences the diffusional process within the polymer system, namely the rate of solvent diffusion 
(RD) and the rate at which polymer chains relax (RR).   
 
In Fickian-type diffusion (case-I), RD is much slower compared RR.  For non-Fickian diffusion (case II, anaomolous 
and super case II) the main differences lies with the RD whereby for case II RR >> RD, for anomalous-type kinetics 
RD ≈ RR and for super case II  RD >> RR 62-65.  Initially, formulations demonstrated Fickian-type diffusion (Table 2) but 
the Korsmeyer-Peppas exponent increased over the stability period to > 0.5 by week 8 moving towards 
anomalous transport (Table 2).  This would suggest that polymer relaxation (swelling/erosion) plays a critical role 
in the release of AMT at earlier stability time points.  The mathematical description and modelling of the casual 
factors for anomalous transport is challenging, and is beyond the scope of this study however a detailed review 
has been published discussing this issue 66.   
 
The mass transport of AMT into the polymer network can be assumed to be comprised of 3 processes 67,68, 
whereby the solvent (water) is absorbed onto the surface of the polymer.  The solvent molecules may then enter 
the lattice network of the polymer, which causes a ‘swelling’ of the network and elongation.  This elongation is 
then counter balanced by an elastic-restrictive force to oppose the swelling.  Eventually a state of equilibrium is 
reached when both forces are balanced, these process can significantly alter the kinetics of drug diffusion 
through the polymer network and are highly influenced by time-scale associated structural changes in the 
polymer 69-72. The move towards anomalous transport over 8 weeks may suggest a polymer network time-
associated affect 73,74, which becomes more apparent over the longer stability study.  The equilibrium between 
swelling and elastic-restrictive force within the polymer may be associated with a time-dependent equilibrium, 
where equilibrium is not established immediately75.  
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Although the formulations are in liquid-phase during the stability storage period, the interactions between both 
mucoadhesive polymers and thermoresponsive polymers may influence eventual formulations of the polymer 
networks, altering the equilibrium processes and hence contributing towards the anomalous transport.  
 
Human nasal epithelial cell culture model: MTT assay 
To investigate the toxicity of amantadine and polymers used within the formulations, a cellular viability study was 
conducted using the human nasal epithelial cell line RPMI 2650.  Cell viability was generally maintained for AMT 
up to 1 mM, with an IC50 of 4.6 mM ± 0.05 mM (Figure 5A) when exposed for 24 hours.  For all polymers tested, 
no significant decrease in cellular viability was observed up to 4 mg/mL (Figure 5B-D) and confirmed the 
formulations developed would be tolerable, from a cellular toxicity perspective, to human nasal epithelia.  
Furthermore, no previous reports have examined the in vitro toxicity profile of AMT towards human nasal 
epithelia and our reports demonstrated that 1 mM would be suitable for prolonged (up to 24 hours) exposure.  
 
Human nasal epithelial airway cell culture model: AMT transport 
The in vitro release of AMT alone and from formulations was further assessed in an in vitro nasal epithelial airway 
cell culture model over 3 hours (Figure 6). 
 
In all formulations a statistically significant (p ≤ 0.01) release of 43-44 % was observed over the duration of the 
transport study in comparison to that of AMT (79 % ± 3.58 %) (Figure 6). The mechanism of release, as described 
by the Korsmeyer-Peppas power law, was modelled according to a super case-II effect (n > 0.89) where the 
sorption of solvent results in breaking of the polymer network (termed solvent crazing) 76 as a result of the 
swelling of the gel within the vitreous nucleus and can be a result of crosslinking density 77, drug loading 78 and 
copolymer composition 79.  The super-case II diffusion of AMT from all gel systems was surprising, and therefore 
the release mechanism of AMT from the formulations is not clear as it is beyond the limits of the power law.  It 
suggests that a rapid release of AMT occurred later in the experiment resulting in rapid relaxation 
governing/controlled transport of AMT from the polymer network 80 81. The ionic composition of the media, 
comprising of a pH of 7.4, may have directly altered the state of ionisation within the polymer gel network, 
compared to the pH of the ANE (pH = 5.5) leading to an altered release profile, with the rapid release being a 
time-dependant reflection of the shift in equilibrium as the solvent (media) penetrates the polymer network 65,75.  
 
Nasal spray systems: droplet size distribution 
Prevention of pulmonary deposition of nasally administered spray formulations is paramount to ensure residency 
within the nasal cavity.  Droplet size distribution is key in determining the potential for pulmonary deposition (< 2 
µm) 82,83, however the droplet size is often dictated by the design of the orifice of the actuator device used to 
deliver the spray plume. For ensuring retention of drug within the nasal passages, droplet sizes of in-excess of 5 
µm are recommended and represented our target cut-off 82,84.   
 
Our formulations all demonstrated a diameter in excess of the traditional cut-off of 5 µm. (Table 3). FCS 
demonstrated a 10% fraction of 7.27 µm ± 0.28 µm (Table 3) closest to the cut-off for pulmonary deposition, 
whereas both FCMC and FPEG were above this.  FCS also demonstrated the smallest diameter (VMD = 92.41 µm 
± 1.72 µm). However, when considering the span of particle sizes, FCS was the broadest (0.96 ± 0.30) with both 
FCMC and FPEG showing a smaller distribution spread (Table 3).  A one-way ANOVA confirmed droplet VMD were 
significantly different across all formulations (p < 0.0001), suggesting that the incorporation of different 
mucoadhesive polymers contributed to the differing polymer sizes with FCS demonstrating the small resulting 
droplets (92.41 µm ± 1.72 µm) and FCMC the largest (120.87 µm ± 0.59 µm).  When considering the viscosity of 
the polymers used in each formulation (Figure 1), CMC resulted in the most viscous formulations and this may 
have contributed to the larger particle sizes, with similar trends observed for CS and PEG. 
 
Nasal spray system: human nasal cast deposition  
To assess the potential in vivo application of formulations, FCS and FCMC were taken forward to assess spray 
deposition within a human nasal cast model. The angle of spray administration was altered from 60-80° and the 
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impact on deposition patterns assed.  For both formulations the administration angle had a significant effect on 
deposition, with an increased angle (80°) having a significantly pronounced localisation in the nasal vestibules 
and lower regions of the nasal cavity.  For FCMC (Figure 7) this deposition area was significantly smaller greater 
than that for FCS (Figure 8).  
 
Interestingly, spray angles of 60° and 70° lead to deposition of the formulation in the olfactory regions of the 
nasal cavity, suggesting the possibility for exploitation in nose-to-brain delivery of amantadine.  FCS sprayed at an 
angle of 60° with insertion lead to olfactory deposition of 0.6-0.7 cm2.  For FCMC a greater olfactory deposition of 
0.91 cm2 was observed at 60° with insertion. Although the higher deposition for FCS may be a result of the 
smaller particle sizes for FCS (92.41 ± 1.72 µm) compared to 120.87 ± 0.59 µm, the impact of nozzle insertion for 
FCMC may enhance delivery onto the olfactory regions (Figure 7 and 8).  When considering the surface area of 
the human olfactory mucosa (2-10 cm2) 85, FCMC may be a viable candidate for further development targeting 
nose-to-brain drug delivery 86. 
 
In both formulations, the impact of head position (15° forward) was important in governing nasal depositions, 
leading to significantly higher deposition within the middle-upper regions of the cast irrespective of the insertion 
angle. 
 
The higher viscosity of FCMC compared to FCS resulted in significantly larger particle sizes (p < 0.001) for the 
optimal formulations and may have resulted in a more focussed (less disperse) spray plume resulting in more 
localised deposition patterns.  In contrast, the lower viscosity of FCS, leading to small particles would lead to a 
wider plume and greater deposition in the nasal cavity 87,88.  
 
As a viable vehicle for nasal or olfactory delivery and residency of formulations within the nasal cavity, the 
optimised formulations demonstrated rapid gelation (FCS: 36.6 s; FCMC: 28 s) (Figure 1) with minimal 
displacement within the nasal cavity (FCS 0.035 cm/s; FCMC: 0.038 cm/s) (Figure 3).  When considering their 
potential residency within the nasal cavity, the sol-gel conversion and displacement would result in minimal nasal 
cavity displacement (FCS: 1.28 cm; FCMC: 1.06 cm).  In-vitro release studies were conducted for 3-hours, with the 
gel structure intact following the release studies, hence the residence in-vivo would be expected to be at least 3-
hours.  Furthermore, the identification of potential nose-to-brain delivery, through olfactory deposition, would 
suggest that these formulations may be adapted to better exploit this ‘direct’ transfer route to the brain. 
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CONCLUSION 
This study has investigated the potential to administer the anti-Parkinsonian drug amantadine through the nasal 
route using a mucoadhesive and thermoresponsive hydrogel formulation systems.  We have demonstrated that 
both carboxymethyl cellulose and chitosan can provide the requirements for mucoadhesion in these 
formulations, whilst also leading to a relatively stable formulation which can be targeted to delivery drug in 
specific regions of the nasal cavity dependant on administration angle and nozzle insertion depth.  Furthermore, 
our results have indicated the potential for nose-to-brain delivery of amantadine, yielding a potentially novel 
avenue therapeutics delivery route to avoid the blood-brain barrier. 
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Figure 1: Rheological analysis of AMT containing thermoresponsive gels containing FCS, FPEG or FCMC. (A): 
Temperature sweep analyses; (B) Time-sweep analyses (fixed at 34 °C). 
 
Figure 2: Shear viscosity analysis of the formulations at ambient (18 °C) and nasal cavity (34 °C) temperature. 
 
Figure 3: Drip transfer of optimised formulations in the presence and absence of mucin-containing agar gel plates 
include at 45° to the plane and maintained at 34 °C. *** p < P 0.001.  
 
Figure 4: Amantadine cumulative % release for optimised formulations following storage at 4°C and 25°C for up 
to 8 weeks. (A) Cumulative % AMT release for samples successfully gelling at nasal cavity temperature (34 °C); (B) 
Comparison of AMT release from FCMC and FCS at preparation (Week 0) and at the end of the stability period 
(Week 8). * p < 0.05, ** p < 0.01. 
 
Figure 5: Cellular toxicity of amantadine, CMC, PEG4000 and F127 on RPMI 2650 cells. Cells were grown on a 96-
well plate and exposed to various concentrations of amantadine (0. 1 nM – 10 mM) or polymer (10-4,000 µg/mL) 
for 24 hours.  Data is reported as mean ± SD with up to 8 replicates per compound in at least 3 independent 
experiments.  
 
Figure 6: Transport of AMT across an in vitro cell culture model of the nasal epithelial, from optimised 
formulations in HBSS-HEPES transport media.  ** p < 0.01. 
  
Figure 7: Representative nasal deposition patterns of FCMC. Brown colours represent the applied Kolor-Kut and 
green colours resent the depositions patterns of the spray. Angles refer to nasal spray position relative to the 
horizontal place (60, 70 or 80°), insertion of the spray orifice into the nostril (5 mm) or with the nasal cast angled 
15° forward.   
 
Figure 8: Representative nasal deposition patterns of FCS.  Brown colours represent the applied Kolor-Kut and 
green colours resent the depositions patterns of the spray. Angles refer to nasal spray position relative to the 
horizontal place (60, 70 or 80°), insertion of the spray orifice into the nostril (5 mm) or with the nasal cast angled 
15° forward. 
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Figure 1: Rheological analysis of AMT containing thermoresponsive gels containing FCS, FPEG or FCMC. (A): 
Temperature sweep analyses; (B) Time-sweep analyses (fixed at 34 °C). 
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Figure 2: Shear viscosity analysis of the formulations at ambient (18 °C) and nasal cavity (34 °C) temperature. 
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Figure 3: Drip transfer of optimised formulations in the presence and absence of mucin-containing agar gel plates 
include at 45° to the plane and maintained at 34 °C. *** p < P 0.001.  
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Figure 4: Amantadine cumulative % release for optimised formulations following storage at 4°C and 25°C for up 
to 8 weeks. (A) Cumulative % AMT release for samples successfully gelling at nasal cavity temperature (34 °C); (B) 
Comparison of AMT release from FCMC and FCS at preparation (Week 0) and at the end of the stability period 
(Week 8). * p < 0.05, ** p < 0.01. 
 
 
  
 25 
 
Figure 5: Cellular toxicity of amantadine, CMC, PEG4000 and F127 on RPMI 2650 cells. Cells were grown on a 96-
well plate and exposed to various concentrations of amantadine (0. 1 nM – 10 mM) or polymer (10-4,000 µg/mL) 
for 24 hours.  Data is reported as mean ± SD with up to 8 replicates per compound in at least 3 independent 
experiments.  
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Figure 6: Transport of AMT across an in vitro cell culture model of the nasal epithelial, from optimised 
formulations in HBSS-HEPES transport media.  ** p < 0.01. 
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Figure 7: Representative nasal deposition patterns of FCMC. Brown colours represent the applied Kolor-Kut and 
green colours resent the depositions patterns of the spray. Angles refer to nasal spray position relative to the 
horizontal place (60, 70 or 80°), insertion of the spray orifice into the nostril (5 mm) or with the nasal cast angled 
15° forward.   
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Figure 8: Representative nasal deposition patterns of FCS.  Brown colours represent the applied Kolor-Kut and 
green colours resent the depositions patterns of the spray. Angles refer to nasal spray position relative to the 
horizontal place (60, 70 or 80°), insertion of the spray orifice into the nostril (5 mm) or with the nasal cast angled 
15° forward. 
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Table 1: Power law rheological analysis of amantadine containing thermoresponsive nasal gels 
 
Formulation Temperature  (°C) k n Behaviour 
FCMC 18 0.157 0.972 Newtonian 
FPEG 18 0.0545 0.971 Newtonian 
FCS 18 0.0656 1 Newtonian 
     FCMC 34 100.2 0.066 Non-Newtonian 
FPEG 34 13.59 0.3043 Non-Newtonian 
FCS 34 56.56 0.1762 Non-Newtonian 
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Table 2:  Drug release kinetics analysis of formulations stored at ambient (18 °C) and nasal cavity (34 °C) 
temperature for up to 8 weeks.   
 
Week Formulation Korsmeyer-Peppas  
4
 °
C
 
0 
FCMC kKP = 2.859 ± 0.899 ; n =0.391 ± 0.051 
FPEG kKP = 2.931 ± 1.160 ; n =0.352 ± 0.076 
FCS kKP = 2.888 ± 0.632 ; n =0.684 ± 0.039 
1 
FCMC kKP = 2.004 ± 0.027 ; n =0.438 ± 0.024 
FPEG kKP = 2.012 ± 0.032 ; n =0.423 ± 0.013 
FCS kKP = 1.852 ± 0.135 ; n =0.433 ± 0.019 
8 
FCMC kKP = 1.034 ± 0.170 ; n =0.538 ± 0.024 
FCS kKP = 1.011 ± 0.092 ; n =0.553 ± 0.024 
2
5
 °
C
 
1 FCS kKP = 1.997 ± 0.659 ; n =0.433 ± 0.059 
2 FCS kKP = 1.614 ± 0.351 ; n =0.474 ± 0.042 
 
kKP: Korsmeyer-Peppas constant; n= release exponent. Mean ± SD. 
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Table 3. Laser diffraction particle size analysis 
 Diameter (µm)  
  Dv10 Dv50 Dv90 VMD Span 
FCS 7.27 ± 0.28 109.07 ± 3.42 157.77 ± 0.99 92.41 ± 1.72 1.38 ± 0.21 
FCMC 39.81 ± 1.02 129.86 ± 0.29 167.39 ± 0.09 120.87 ± 0.59 0.98 ± 0.30 
FPEG 43.93 ± 0.88 104.67 ± 1.88 150.95 ± 1.04 100.35 ± 1.53 1.02 ± 0.06 
Mean ±SD, 6 replicate spray actuations per formulation. 
Dv10: 10 % of the cumulative undersized (volume) fraction; Dv50: 50 % of the cumulative undersized (volume) 
fraction; Dv90: 90 % of the cumulative undersized (volume) fraction; VMD: volume mean diameter; Span: relative 
span (Dv90-Dv10)/Dv50. 
 
 
